Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 267Magnetic Resonance Spectroscopy 218pembrolizumab 203Carboplatin 170Cisplatin 137Biopsy 136Cyclophosphamide 131Paclitaxel 120Nivolumab 110Bevacizumab 104Gemcitabine 102Radiotherapy 85Dexamethasone 77Pemetrexed 75atezolizumab 73Fluorouracil 71fludarabine 69Doxorubicin 68Leucovorin 66Docetaxel 66Radiation 65Oxaliplatin 62Rituximab 60venetoclax 58Prednisone 58Cetuximab 54durvalumab 53Vincristine 52Etoposide 51130-nm albumin-bound paclitaxel 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
surufatinib × 30 days × Clear all
NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Hutchmed

Phase 2/3 Recruiting
502 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07609121 2026-05-27

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

Sun Yat-sen University

Phase 2 Not yet recruiting
160 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡